FY2024 EPS Estimates for Balchem Co. (NASDAQ:BCPC) Lifted by HC Wainwright

Balchem Co. (NASDAQ:BCPC) – Stock analysts at HC Wainwright boosted their FY2024 EPS estimates for shares of Balchem in a research report issued to clients and investors on Wednesday, July 31st. HC Wainwright analyst R. Selvaraju now expects that the basic materials company will post earnings of $3.81 per share for the year, up from their previous forecast of $3.71. HC Wainwright has a “Buy” rating and a $185.00 price objective on the stock. The consensus estimate for Balchem’s current full-year earnings is $3.91 per share. HC Wainwright also issued estimates for Balchem’s Q4 2024 earnings at $0.99 EPS.

Separately, StockNews.com lowered shares of Balchem from a “buy” rating to a “hold” rating in a report on Monday, July 29th.

Balchem Trading Up 0.5 %

NASDAQ:BCPC opened at $165.16 on Monday. Balchem has a one year low of $110.74 and a one year high of $186.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The firm has a market cap of $5.35 billion, a P/E ratio of 46.66, a P/E/G ratio of 5.63 and a beta of 0.68. The firm has a 50-day simple moving average of $161.58 and a 200-day simple moving average of $154.11.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of BCPC. Norges Bank acquired a new position in Balchem during the 4th quarter valued at approximately $52,233,000. APG Asset Management US Inc. acquired a new position in Balchem during the 4th quarter valued at approximately $39,164,000. Corient Private Wealth LLC increased its stake in Balchem by 4,678.4% during the 4th quarter. Corient Private Wealth LLC now owns 262,671 shares of the basic materials company’s stock valued at $39,072,000 after purchasing an additional 257,174 shares in the last quarter. Vanguard Group Inc. increased its stake in Balchem by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock valued at $609,873,000 after purchasing an additional 144,423 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in Balchem during the 1st quarter valued at approximately $19,771,000. Institutional investors own 87.91% of the company’s stock.

Insider Activity

In related news, insider William A. Backus 3,900 shares of the firm’s stock in a transaction on Tuesday, July 30th. The was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, SVP Michael Robert Sestrick sold 1,929 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $154.45, for a total transaction of $297,934.05. Following the completion of the transaction, the senior vice president now owns 4,878 shares in the company, valued at approximately $753,407.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William A. Backus 3,900 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The disclosure for this trade can be found here. Company insiders own 1.25% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.